Medistim ASA (OSL:MEDI)
Norway · Delayed Price · Currency is NOK 250.00
-3.00 (-1.19%)
Oct 2, 2026, 4:26 PM CET
Medistim ASA Ratios and Metrics
Market cap in millions NOK. Fiscal year is January - December.
Millions NOK. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 4,573 | 4,735 | 2,738 | 3,912 | 4,216 | 6,693 | |
Market Cap Growth | 11.23% | 72.95% | -30.01% | -7.22% | -37.01% | 47.10% |
Enterprise Value | 4,508 | 4,599 | 2,618 | 3,790 | 4,111 | 6,629 |
Last Close Price | 250.00 | 249.91 | 139.12 | 194.33 | 206.52 | 323.85 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 27.65 | 29.74 | 26.37 | 37.68 | 36.99 | 73.64 |
Forward PE | 23.98 | 29.10 | 25.34 | 33.80 | 39.94 | 61.56 |
PS Ratio | 6.07 | 6.77 | 4.87 | 7.51 | 8.67 | 16.02 |
PB Ratio | 11.13 | 10.11 | 6.27 | 9.83 | 11.47 | 21.87 |
P/TBV Ratio | 14.77 | 12.39 | 7.28 | 11.10 | 12.71 | 24.26 |
P/FCF Ratio | 25.38 | 26.08 | 19.98 | 38.05 | 40.45 | 55.79 |
P/OCF Ratio | 24.63 | 25.31 | 19.13 | 32.82 | 37.15 | 52.55 |
PEG Ratio | - | 2.15 | 2.15 | 2.32 | 1.25 | 1.25 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 5.99 | 6.57 | 4.65 | 7.27 | 8.45 | 15.87 |
EV/EBITDA Ratio | 19.76 | 21.67 | 17.88 | 25.83 | 26.11 | 52.09 |
EV/EBIT Ratio | 21.96 | 23.44 | 19.97 | 28.83 | 29.10 | 59.73 |
EV/FCF Ratio | 25.02 | 25.33 | 19.11 | 36.86 | 39.43 | 55.26 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.09 | 0.11 | 0.08 | 0.04 | 0.05 | 0.08 |
Debt / EBITDA Ratio | 0.15 | 0.22 | 0.22 | 0.11 | 0.10 | 0.18 |
Debt / FCF Ratio | 0.19 | 0.27 | 0.25 | 0.17 | 0.16 | 0.20 |
Net Debt / Equity Ratio | -0.16 | -0.35 | -0.33 | -0.34 | -0.37 | -0.34 |
Net Debt / EBITDA Ratio | -0.30 | -0.77 | -0.99 | -0.93 | -0.86 | -0.83 |
Net Debt / FCF Ratio | -0.36 | -0.90 | -1.06 | -1.32 | -1.30 | -0.88 |
Asset Turnover | 1.35 | 1.13 | 1.04 | 1.05 | 1.10 | 1.12 |
Inventory Turnover | 0.87 | 0.80 | 0.74 | 0.87 | 1.01 | 0.93 |
Quick Ratio | 1.88 | 2.16 | 2.41 | 2.53 | 2.64 | 2.62 |
Current Ratio | 3.15 | 3.34 | 4.00 | 4.15 | 3.87 | 3.95 |
Return on Equity (ROE) | 41.59% | 35.18% | 24.88% | 27.12% | 33.83% | 32.30% |
Return on Assets (ROA) | 22.97% | 19.85% | 15.16% | 16.62% | 19.93% | 18.52% |
Return on Invested Capital (ROIC) | 46.77% | 50.56% | 36.63% | 40.87% | 50.92% | 41.64% |
Return on Capital Employed (ROCE) | 44.70% | 37.90% | 28.00% | 31.90% | 36.90% | 34.10% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 3.61% | 3.36% | 3.79% | 2.65% | 2.70% | 1.36% |
FCF Yield | 3.94% | 3.84% | 5.00% | 2.63% | 2.47% | 1.79% |
Dividend Yield | 3.20% | 3.20% | 4.31% | 2.32% | 2.18% | 1.16% |
Payout Ratio | 88.28% | 68.75% | 79.37% | 79.15% | 60.01% | 60.11% |
Buyback Yield / Dilution | 0.06% | 0.21% | -0.10% | -0.10% | -0.15% | -0.07% |
Total Shareholder Return | 3.26% | 3.41% | 4.21% | 2.21% | 2.03% | 1.09% |